Recent Updates — INBS

The Board of Directors adopted the Second Amended and Restated Bylaws, effective October 12, 2026. The changes revise Section 2.6 to clarify that any matter other than director elections brought before a stockholder meeting will be decided by the affirmative vote of holders of a majority in voting power of votes cast, excluding broker non-votes and abstentions. This governance update standardizes the voting threshold for routine corporate actions. Intelligent Bio Solutions Inc. operates as a biotechnology company focused on developing therapeutic products.

Intelligent Bio Solutions submitted a 510(k) premarket notification to the U.S. Food and Drug Administration on September 9, 2026, seeking regulatory clearance for its Intelligent Fingerprinting Drug Screening System to detect codeine. The submission includes clinical data from over 18,000 hours of testing across three independent sites, demonstrating accuracy above 98%, sensitivity above 94%, and 100% specificity. The company operates in the medical technology industry, providing rapid, non-invasive drug screening solutions.

Intelligent Bio Solutions Inc. closed a private placement on September 2, 2026, issuing 2,036,659 shares and associated warrants to a single institutional investor for approximately $5.0 million in gross proceeds. The transaction includes Series N-1 and Series N-2 warrants exercisable at $2.33 per share, with the N-1 warrants callable upon FDA 510(k) clearance of its drug screening system. Proceeds are designated for working capital and general corporate purposes. Intelligent Bio Solutions Inc. operates in the medical technology industry, developing non-invasive testing solutions such as fingerprint-based drug screening systems.